Immunotherapy against cancer: How therapeutic antibodies do their job

A new super-resolution microscopic method

13-Jan-2025 - A new look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers from the University of Würzburg have observed for the first time with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their destruction. The ...

Revolutionary Breakthrough: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing Genes

Scientists demonstrate the therapeutic value of a compound that inhibits oncogene translation

20-Jul-2023 - In a remarkable new development, scientists at the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH) have demonstrated the powerful impact of a drug in slowing down the progression of leukaemia by blocking the activation of cancer-causing genes. The findings, ...

Master hijackers: uncovering how leukaemia disarms the body’s defences

Microscopic vesicles released from leukaemia tumours and their surrounding cells prove critical in obstructing the body’s ability to fight cancer

19-Oct-2022 - A study led by the Tumor Stroma Interactions group at the Luxembourg Institute of Health has discovered that microscopic vesicles released by tumours and their surrounding cells in mice with chronic lymphocytic leukaemia hijack a specific branch of the body’s immune system and prevent it from ...

Discovery of a gene that causes chronic lymphocytic leukemia

CSIC researchers lead a study that shows that more than 82% of patients with this pathology have high levels of the RRAS2 gene.

11-Feb-2022 - CSIC researchers, with the support of the Spanish Association Against Cancer, lead a study that has identified a gene that, without the need for mutations, causes chronic lymphocytic leukemia, the most common in people over sixty years of age. The finding, published in Molecular Cancer, shows ...

Moderate immune response is more effective against leukemia

While the working hypothesis so far has been mainly toactivate T cells as strong as possible, the current results refine this view

10-Dec-2021 - The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune ...

Tracing the path of leukemia

Chemical signature of chronic lymphocytic leukemia already present in the precancerous stage

26-Jan-2021 - B-cell lymphocytosis, a condition in which individuals have increased levels of particular white blood cells, in some cases leads to blood cancer. As an international team of researchers now shows in samples from patients, both diseases exhibit similar epigenetic signatures that are forming very ...

A potent weapon against lymphomas

Mice with leukemia were cured

19-Jan-2021 - MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults. The ...

A potential new target for immunotherapies in cancer

Compounds that inhibit metabolic enzyme IL4I1 could open up new opportunities for cancer therapy

24-Aug-2020 - The metabolic enzyme IL4I1 (interleukin-4-induced-1) promotes the spread of tumor cells and suppresses the immune system. This was discovered by scientists from the Berlin Institute of Health (BIH) together with colleagues from the German Cancer Research Center (DKFZ) in Heidelberg. The enzyme is ...

A combination drug trial to eradicate B-cell malignancies launched

13-Mar-2018 - Fueled by a multimillion dollar grant from the state's stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined ...

New driver, target in advanced mucosal melanoma

16-Mar-2017 - Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted treatments and immunotherapies have dramatically improved the prognosis for many patients with ...